What is the onset, peak, and duration of action of intravenous (IV) morphine (opioid analgesic)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Intravenous (IV) morphine begins working very quickly, typically within 5-10 minutes after administration, with a peak effect occurring around 20-30 minutes after injection, and the pain-relieving effects generally lasting for 3-4 hours. The onset of action, peak effect, and duration of action can vary depending on several factors, including the dose administered, individual patient characteristics, and the specific clinical context. According to the provided evidence, particularly from 1, the recommended dose of morphine for acute moderate-severe pain is 0.1 mg/kg, with a maximum suggested dose of 10 mg, and it is suggested to give 0.05 mg/kg at 30 min.

The duration of action and how long morphine stays in the system can also be influenced by factors such as age, weight, liver and kidney function, metabolism, and whether the patient uses morphine regularly. For instance, elderly patients and those with impaired liver or kidney function may experience longer durations of effects and extended elimination times. Morphine is metabolized primarily by the liver and excreted through the kidneys, and its detection in the body varies by testing method: 12 hours in blood, 2-3 days in urine, up to 90 days in hair, and about 24 hours in saliva, as noted in general medical knowledge and supported by principles outlined in 1 and 1.

It's crucial to consider the potential side effects of morphine, including respiratory depression, especially at higher doses or when combined with other central nervous system depressants. The management of acute pain with morphine, as discussed in 1, emphasizes the importance of relief of pain, breathlessness, and anxiety in patients, highlighting the use of intravenous opioids like morphine for analgesia.

Key points to consider in the administration of IV morphine include:

  • Onset of action: 5-10 minutes
  • Peak effect: 20-30 minutes
  • Duration of action: 3-4 hours
  • Factors affecting duration and elimination: age, weight, liver and kidney function, metabolism, dosage, and regular use
  • Potential side effects: respiratory depression, nausea, vomiting, hypotension, and bradycardia
  • Importance of monitoring and adjusting doses based on individual patient response and clinical context, as recommended in 1.

From the Research

Morphine IV Onset and Duration

  • The onset of morphine IV is rapid, with peak plasma levels achieved within a short time frame 2.
  • The exact time to peak plasma levels after IV administration is not specified in the provided studies, but it is known that morphine is rapidly distributed after absorption 3, 2.
  • The elimination half-life of morphine is approximately 2.9 hours after IV administration, indicating that the drug stays in the system for several hours 2.

Peak and Duration of Action

  • The peak effect of morphine IV is typically seen within 15-30 minutes after administration, although this can vary depending on individual factors 3, 2.
  • The duration of action of morphine IV is approximately 4-6 hours, although this can also vary depending on individual factors and the dose administered 2, 4.
  • Morphine and its metabolites are excreted by the kidney, and the drug can accumulate in patients with renal insufficiency, potentially prolonging its effects 3.

Factors Affecting Morphine Pharmacokinetics

  • The pharmacokinetics of morphine can be affected by various factors, including age, liver function, and renal function 3, 4.
  • Elderly patients may have a longer elimination half-life and reduced clearance of morphine, potentially increasing the risk of adverse effects 2.
  • Patients with liver disease may require reduced doses of morphine due to impaired metabolism, while those with renal insufficiency may experience accumulation of the drug and its metabolites 3.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Kinetics of intravenous and intramuscular morphine.

Clinical pharmacology and therapeutics, 1978

Research

Clinical pharmacokinetics of morphine.

Therapeutic drug monitoring, 1991

Research

Clinical pharmacokinetics of morphine.

Journal of pain & palliative care pharmacotherapy, 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.